Market Overview

Wedbush Downgrades Smith & Wesson, Difficult To Discern How Much Gun Sales Are Incremental Or Pulled-Forward

Wedbush Downgrades Smith & Wesson, Difficult To Discern How Much Gun Sales Are Incremental Or Pulled-Forward
  • Shares of Smith & Wesson Holding Corp (NASDAQ: SWHC) have surged 172.78 percent over the past year, rising to a high of $25.86 on Monday.
  • Wedbush’s James Hardiman has downgraded the rating on the company from Outperform to Neutral, while raising the price target from $24 to $26.
  • The downgrade is based on the “healthy” valuation of the stock, following the more than 150 percent surge in the share price over the past year.

According to the Wedbush report, “While gun industry sales are clearly in ‘surge’ mode, it is difficult to discern just how much of these sales are in fact incremental to the industry versus pulled-forward demand, with plenty of historical examples of both.”

Related Link: Gun Stocks Continue To Rise Following President Obama's Teary-Eyed Speech

Smith and Wesson announced an increase in its non-GAAP EPS guidance for 3Q16 and FY16 after market close on January 4. Management now expects the 3Q EPS at $0.39-$0.41, twice that reported a year ago and significantly higher than the previous guidance, as well as the consensus and estimate. Q3 sales are now expected at $175-$180 million, also ahead of the estimate and the consensus.

Analyst James Hardiman explained that this revision “comes on the heels of extremely strong background check (NICS) data, up 38 percent in the month of December, a significant acceleration versus the 8% growth in November.”

Hardiman also mentioned that based on the Q2 performance, the company was likely to see significant market share gains in both handguns and long guns.

The EPS estimates for FY16 and FY17 have been raised from $1.34 to $1.47 and from $1.47 to $1.55, respectively.

Disclosure: Javier Hasse holds no stakes in any of the securities mentioned above.

Image Credit: Public Domain

Latest Ratings for SWHC

Nov 2016DowngradesBuyHold
Oct 2016DowngradesBuyHold
Jun 2016UpgradesMarket PerformOutperform

View More Analyst Ratings for SWHC
View the Latest Analyst Ratings

Posted-In: James Hardiman WedbushAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (SWHC)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

DURECT Announces Positive Phase 1 Data for DUR-928

Washington University Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer